The GLP-1 receptor agonists, liraglutide and semaglutide, appear to represent a first-line option in obese patients with NAFLD and T2DM since they induce considerable weight loss and have been extensively studied in patients with T2DM. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.